IL133196A0 - Gastroretentive controlled release pharmaceutical dosage forms - Google Patents

Gastroretentive controlled release pharmaceutical dosage forms

Info

Publication number
IL133196A0
IL133196A0 IL13319699A IL13319699A IL133196A0 IL 133196 A0 IL133196 A0 IL 133196A0 IL 13319699 A IL13319699 A IL 13319699A IL 13319699 A IL13319699 A IL 13319699A IL 133196 A0 IL133196 A0 IL 133196A0
Authority
IL
Israel
Prior art keywords
polymers
controlled release
dosage forms
pharmaceutical dosage
release pharmaceutical
Prior art date
Application number
IL13319699A
Other languages
English (en)
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Priority to IL13319699A priority Critical patent/IL133196A0/xx
Priority to JP2001539427A priority patent/JP4679020B2/ja
Priority to AT00978993T priority patent/ATE300286T1/de
Priority to EP00978993A priority patent/EP1235557B1/fr
Priority to IL14985300A priority patent/IL149853A0/xx
Priority to DE60021604T priority patent/DE60021604T2/de
Priority to RU2002114348/15A priority patent/RU2002114348A/ru
Priority to AU16477/01A priority patent/AU783062B2/en
Priority to CA002392361A priority patent/CA2392361C/fr
Priority to ES00978993T priority patent/ES2243327T3/es
Priority to PCT/IL2000/000774 priority patent/WO2001037812A2/fr
Publication of IL133196A0 publication Critical patent/IL133196A0/xx
Priority to IL149853A priority patent/IL149853A/en
Priority to ZA200204268A priority patent/ZA200204268B/xx
Priority to US10/157,325 priority patent/US6685962B2/en
Priority to AU2005256098A priority patent/AU2005256098A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13319699A 1999-11-29 1999-11-29 Gastroretentive controlled release pharmaceutical dosage forms IL133196A0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
IL13319699A IL133196A0 (en) 1999-11-29 1999-11-29 Gastroretentive controlled release pharmaceutical dosage forms
AU16477/01A AU783062B2 (en) 1999-11-29 2000-11-20 Gastroretentive controlled release pharmaceutical dosage forms
CA002392361A CA2392361C (fr) 1999-11-29 2000-11-20 Formes posologiques pharmaceutiques a liberation regulee contre la retention gastrique
EP00978993A EP1235557B1 (fr) 1999-11-29 2000-11-20 Formes posologiques pharmaceutiques a liberation regulee contre la retention gastrique
IL14985300A IL149853A0 (en) 1999-11-29 2000-11-20 Gastroretentive controlled release pharmaceutical dosage forms
DE60021604T DE60021604T2 (de) 1999-11-29 2000-11-20 Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
RU2002114348/15A RU2002114348A (ru) 1999-11-29 2000-11-20 Удерживаемые в желудке фармацевтические лекарственные формы с контролируемым высвобождением
JP2001539427A JP4679020B2 (ja) 1999-11-29 2000-11-20 胃内滞留性制御放出医薬剤形
AT00978993T ATE300286T1 (de) 1999-11-29 2000-11-20 Gastroretentive pharmazeutische dosierungsformen mit gesteuerten abgaben
ES00978993T ES2243327T3 (es) 1999-11-29 2000-11-20 Formas de dosificacion farmaceuticas de liberacion gastrorretentiva controlada.
PCT/IL2000/000774 WO2001037812A2 (fr) 1999-11-29 2000-11-20 Formes posologiques pharmaceutiques a liberation regulee contre la retention gastrique
IL149853A IL149853A (en) 1999-11-29 2002-05-26 Gastroretentive controlled release pharmaceutical dosage forms
ZA200204268A ZA200204268B (en) 1999-11-29 2002-05-28 Gastroretentive controlled release pharmaceutical dosage forms.
US10/157,325 US6685962B2 (en) 1999-11-29 2002-05-29 Gastroretentive controlled release pharmaceutical dosage forms
AU2005256098A AU2005256098A1 (en) 1999-11-29 2005-12-22 Gastroretentive controlled release pharmaceutical dosage forms

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL13319699A IL133196A0 (en) 1999-11-29 1999-11-29 Gastroretentive controlled release pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
IL133196A0 true IL133196A0 (en) 2001-03-19

Family

ID=11073546

Family Applications (2)

Application Number Title Priority Date Filing Date
IL13319699A IL133196A0 (en) 1999-11-29 1999-11-29 Gastroretentive controlled release pharmaceutical dosage forms
IL149853A IL149853A (en) 1999-11-29 2002-05-26 Gastroretentive controlled release pharmaceutical dosage forms

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL149853A IL149853A (en) 1999-11-29 2002-05-26 Gastroretentive controlled release pharmaceutical dosage forms

Country Status (12)

Country Link
US (1) US6685962B2 (fr)
EP (1) EP1235557B1 (fr)
JP (1) JP4679020B2 (fr)
AT (1) ATE300286T1 (fr)
AU (1) AU783062B2 (fr)
CA (1) CA2392361C (fr)
DE (1) DE60021604T2 (fr)
ES (1) ES2243327T3 (fr)
IL (2) IL133196A0 (fr)
RU (1) RU2002114348A (fr)
WO (1) WO2001037812A2 (fr)
ZA (1) ZA200204268B (fr)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040219186A1 (en) * 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
TWI312285B (en) * 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
AUPR951501A0 (en) * 2001-12-14 2002-01-24 Smart Drug Systems Inc Modified sustained release pharmaceutical system
WO2005023331A2 (fr) * 2003-09-04 2005-03-17 The United States Of America As Represented By The Department Of Veterans Affairs Nanocomposites d'hydrogel pour applications ophtalmiques
AU2003299838A1 (en) 2002-12-19 2004-07-14 Polymorfix, Inc. Ingestible formulations for transient, noninvasive reduction of gastric volume
US7554452B2 (en) * 2003-07-18 2009-06-30 Cary Cole Ingestible tracking and locating device
EP1673073A4 (fr) * 2003-09-29 2012-03-21 Cj Cheiljedang Corp Formulations a liberation lente
AU2004296404A1 (en) * 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20080089933A1 (en) 2006-10-16 2008-04-17 Amir Alon Device and method for reducing calorie intake
US20050196355A1 (en) * 2004-03-03 2005-09-08 Constantine Georgiades Film products having controlled disintegration properties
US8007827B2 (en) * 2004-04-02 2011-08-30 Impax Laboratories, Inc. Pharmaceutical dosage forms having immediate release and/or controlled release properties
CA2568640C (fr) 2004-06-04 2011-08-09 Teva Pharmaceutical Industries Ltd. Composition pharmaceutique contenant de l'irbesartan
US20080311191A1 (en) * 2004-08-27 2008-12-18 Avinash Nangia Multi-Layer Tablets and Bioadhesive Dosage Forms
US20060246003A1 (en) * 2004-12-27 2006-11-02 Eisai Co. Ltd. Composition containing anti-dementia drug
US20070129402A1 (en) * 2004-12-27 2007-06-07 Eisai Research Institute Sustained release formulations
US8481565B2 (en) * 2004-12-27 2013-07-09 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
US20060280789A1 (en) * 2004-12-27 2006-12-14 Eisai Research Institute Sustained release formulations
IL166183A0 (en) * 2005-01-06 2006-01-15 Yissum Res Dev Co Novel diagnostic and imaging techniques of the gi tract
KR100822519B1 (ko) * 2005-02-15 2008-04-16 주식회사종근당 위장 내에서 제어방출되는 단일 매트릭스 정제
WO2007041079A2 (fr) * 2005-09-30 2007-04-12 Alza Corporation Formes posologiques a liberation regulee a bandelettes renfermant des preparations d'agents actifs nanoparticulaires
US20070092565A1 (en) * 2005-10-25 2007-04-26 Pharmascience Inc. Gastric retention drug delivery system
HUE027282T2 (en) 2006-01-18 2016-11-28 Intec Pharma Ltd A method for preparing a dosing device for oral administration of the agent
WO2007093999A1 (fr) * 2006-02-15 2007-08-23 Intec Pharma Ltd. Système de gastro-rétention pour dé livrer des macromolécules
WO2007103286A2 (fr) * 2006-03-02 2007-09-13 Spherics, Inc. Formulations posologiques orales a liberation controlee
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
NZ598728A (en) 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
WO2008115597A2 (fr) * 2007-03-21 2008-09-25 Cytologic, Inc. Mutéines de cytokine et procédés pour amplifier des réponses immunitaires chez des mammifères
DK2192946T3 (da) 2007-09-25 2022-11-21 Otsuka Pharma Co Ltd Kropsintern anordning med virtuel dipol signalforstærkning
ES2463774T3 (es) 2007-11-12 2014-05-29 Pharmaceutics International, Inc. Complejos trimoleculares y su uso en sistemas de administración de fármacos
US8771730B2 (en) * 2008-04-18 2014-07-08 Intec Pharma Ltd. Carbidopa/Levodopa gastroretentive drug delivery
US7981760B2 (en) * 2008-05-08 2011-07-19 Panasonic Corporation Method for manufacturing nonvolatile storage element and method for manufacturing nonvolatile storage device
US8287902B2 (en) * 2008-07-23 2012-10-16 Rainbow Medical Ltd. Enhanced-diffusion capsule
PL2378883T3 (pl) * 2008-12-04 2016-06-30 Intec Pharma Ltd SYSTEM DOSTARCZANIA LEKU ZATRZYMYWANEGO W ŻOŁĄDKU dLA ZALEPLONU
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
CA2758976C (fr) 2009-04-20 2015-02-03 Alain Baron Therapies a base de ligand de recepteur chimiosensible
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US8414559B2 (en) * 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
US20110066175A1 (en) * 2009-05-07 2011-03-17 Rainbow Medical Ltd. Gastric anchor
US20100286628A1 (en) * 2009-05-07 2010-11-11 Rainbow Medical Ltd Gastric anchor
WO2011048494A2 (fr) * 2009-10-19 2011-04-28 Intec Pharma Ltd. Nouvelles formes pharmaceutiques à rétention gastrique de médicaments peu solubles
CA2780274C (fr) 2009-11-09 2018-06-26 Spotlight Technology Partners Llc Hydrogels fragmentes
WO2011057131A1 (fr) 2009-11-09 2011-05-12 Spotlight Technology Partners Llc Hydrogels à base de polysaccharide
EP3360916A1 (fr) 2009-12-18 2018-08-15 Coloplast A/S Biomatériau
WO2011073968A1 (fr) * 2009-12-18 2011-06-23 Vysera Biomedical Limited Système d'administration de médicament
EP2544666A2 (fr) 2010-03-09 2013-01-16 Council of Scientific and Industrial Research Composition gastro-rétentive d'agent thérapeutique à libération prolongée
US8628554B2 (en) 2010-06-13 2014-01-14 Virender K. Sharma Intragastric device for treating obesity
US9526648B2 (en) 2010-06-13 2016-12-27 Synerz Medical, Inc. Intragastric device for treating obesity
US10420665B2 (en) 2010-06-13 2019-09-24 W. L. Gore & Associates, Inc. Intragastric device for treating obesity
US10010439B2 (en) 2010-06-13 2018-07-03 Synerz Medical, Inc. Intragastric device for treating obesity
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
EP2630491A4 (fr) 2010-10-19 2014-08-27 Elcelyx Therapeutics Inc Thérapies basées sur un ligand de récepteur chimiosensoriel
PT2661266T (pt) 2011-01-07 2020-11-30 Anji Pharma Us Llc Terapias com base em ligandos do recetor quimiossensorial
US8722066B2 (en) 2011-03-29 2014-05-13 Primigenia, LLC Devices and methods for weight control and weight loss
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2013158928A2 (fr) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Thérapies à base de ligand de récepteur chimiosensoriels
WO2014039951A1 (fr) 2012-09-10 2014-03-13 Novartis Ag Compositions pharmaceutiques entérales
WO2014174496A1 (fr) * 2013-04-25 2014-10-30 Ranbaxy Laboratories Limited Forme posologique orale solide de produit pharmaceutique à rétention gastrique de nilotinib
JP2016520653A (ja) 2013-06-05 2016-07-14 シンクロニューロン インコーポレイテッド アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
WO2015091885A2 (fr) * 2013-12-20 2015-06-25 Fresenius Kabi Deutschland Gmbh Microcapsules avec un revêtement polymère comprenant un lipide et un agent actif
CA2949372C (fr) 2014-06-02 2023-08-22 Teva Pharmaceutical Industries Ltd. Forme posologique a retention gastrique expansible
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
RU2766335C2 (ru) 2014-06-11 2022-03-15 Массачусетс Инститьют Оф Текнолоджи Удерживаемые структуры и связанные способы
US9492396B2 (en) 2014-07-15 2016-11-15 Yossi Gross Enhanced drug delivery pill
CN108653221B (zh) * 2015-06-03 2021-09-07 南京三迭纪医药科技有限公司 药品剂型及其使用
EP4512394A3 (fr) * 2015-06-03 2025-10-22 Triastek, Inc. Formes galéniques et leur utilisation
CA2989581A1 (fr) 2015-06-17 2016-12-22 Biogen Ma Inc. Particules de fumarate de dimethyle et leurs compositions pharmaceutiques
CN108472249A (zh) 2015-10-23 2018-08-31 林德拉有限公司 用于治疗剂缓释的胃驻留系统及其使用方法
EP3368010B1 (fr) * 2015-10-26 2025-12-10 Blaesi, Aron H. Forme galénique solide à libération immédiate de médicament et appareil et procédé de fabrication associés
US11129798B2 (en) 2016-08-19 2021-09-28 Aron H. Blaesi Fibrous dosage form
US11478427B2 (en) * 2015-10-26 2022-10-25 Aron H. Blaesi Dosage form comprising structural framework of two-dimensional elements
EP3383365A1 (fr) * 2015-12-01 2018-10-10 Clexio Biosciences Ltd. Dispositifs de rétention gastrique
WO2017093976A1 (fr) * 2015-12-02 2017-06-08 Teva Pharmaceutical Industries Ltd. Dispositif de préparation de formes pharmaceutiques à rétention gastrique
EP3386488B1 (fr) 2015-12-08 2023-09-06 Lyndra Therapeutics, Inc. Configurations géométriques de systèmes à résidence gastrique
IL261756B2 (en) 2016-03-17 2023-11-01 Thiogenesis Therapeutics Inc Preparations for the controlled release of cysteamine and systemic treatment of disorders sensitive to cysteamine
US10779980B2 (en) 2016-04-27 2020-09-22 Synerz Medical, Inc. Intragastric device for treating obesity
CN109310639A (zh) 2016-05-27 2019-02-05 林德拉有限公司 用于胃驻留系统的材料结构
CA3027700A1 (fr) * 2016-07-11 2018-01-18 Intec Pharma Ltd. Formulations orales a retention gastrique et utilisations de celles-ci
JP2019532947A (ja) 2016-09-30 2019-11-14 リンドラ，インコーポレイティド アダマンタン系薬物の持続的送達のための胃内滞留システム
EP3547974B1 (fr) 2016-12-02 2023-11-15 Clexio Biosciences Ltd. Système à résidence gastrique
CA3051614A1 (fr) 2017-01-26 2018-08-02 Triastek, Inc. Formes posologiques de liberation controlee a des sites gastro-intestinaux specifiques
EP3634382A4 (fr) 2017-06-09 2021-07-07 Lyndra Therapeutics, Inc. Systèmes gastriques à demeure avec films modulant le taux de libération
ES3024932T3 (en) 2017-09-20 2025-06-05 Thiogenesis Therapeutics Inc Compounds for the treatment of cysteamine sensitive disorders
WO2019111132A1 (fr) 2017-12-04 2019-06-13 Clexio Biosciences Ltd. Système de résidence gastrique à action prolongée
US11571391B2 (en) 2018-01-09 2023-02-07 Triastek, Inc. Oral drug dosage forms compromising a fixed-dose of an ADHD non-stimulant and an ADHD stimulant
WO2019223753A1 (fr) 2018-05-23 2019-11-28 上海汉都医药科技有限公司 Système à libération contrôlée d'un principe actif pharmaceutique et son procédé de préparation
US11911513B2 (en) 2018-05-23 2024-02-27 Shanghai Wd Pharmaceutical Co., Ltd Controlled-release system of active pharmaceutical ingredient and preparation method therefor
CN114191307A (zh) 2020-09-17 2022-03-18 上海汉都医药科技有限公司 一种口腔滞留装置及其制备方法
US10675248B2 (en) 2018-08-14 2020-06-09 Alma Therapeutics Ltd. Expandable pill
PT4037666T (pt) 2020-12-08 2024-06-25 Ruminant Biotech Corp Ltd Aperfeiçoamentos de dispositivos e métodos para administração de substâncias a animais
US12458588B2 (en) 2021-05-20 2025-11-04 E Ink Corporation Benefit agent delivery system using electroplating

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3574820A (en) 1968-01-08 1971-04-13 Upjohn Co Medicinal dosage forms of unpolymerized thiolated gelatin with a cross-linking accelerating agent providing slowly released medication from a swollen matrix
US4207890A (en) 1977-01-04 1980-06-17 Mcneilab, Inc. Drug-dispensing device and method
US4434153A (en) 1982-03-22 1984-02-28 Alza Corporation Drug delivery system comprising a reservoir containing a plurality of tiny pills
US4735804A (en) 1985-05-10 1988-04-05 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4758436A (en) 1985-05-29 1988-07-19 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
US5047464A (en) 1989-09-20 1991-09-10 Merck & Co., Inc. Bioerodible thermoset elastomers
US5217712A (en) 1989-09-20 1993-06-08 Merck & Co., Inc. Bioerodible thermoset elastomers
IT1265240B1 (it) * 1993-11-30 1996-10-31 Ekita Investments Nv Compressa farmaceutica a rilascio controllato, di forma lenticolare
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system

Also Published As

Publication number Publication date
CA2392361A1 (fr) 2001-05-31
IL149853A (en) 2006-12-31
RU2002114348A (ru) 2004-01-10
CA2392361C (fr) 2010-01-19
ATE300286T1 (de) 2005-08-15
AU783062B2 (en) 2005-09-22
DE60021604T2 (de) 2006-06-01
WO2001037812A2 (fr) 2001-05-31
ES2243327T3 (es) 2005-12-01
US6685962B2 (en) 2004-02-03
EP1235557B1 (fr) 2005-07-27
WO2001037812A3 (fr) 2002-02-21
EP1235557A2 (fr) 2002-09-04
JP4679020B2 (ja) 2011-04-27
JP2003514845A (ja) 2003-04-22
DE60021604D1 (de) 2005-09-01
AU1647701A (en) 2001-06-04
ZA200204268B (en) 2003-08-28
US20030021845A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
ZA200204268B (en) Gastroretentive controlled release pharmaceutical dosage forms.
Debotton et al. Applications of polymers as pharmaceutical excipients in solid oral dosage forms
US6632451B2 (en) Delayed total release two pulse gastrointestinal drug delivery system
EP1021171B1 (fr) Systeme d'administration de medicaments a liberation totale prolongee destines au tractus gastro-intestinal
US6531152B1 (en) Immediate release gastrointestinal drug delivery system
CA2446712C (fr) Systeme d'administration osmotique d'agents pharmaceutiquement actifs
CA2014451A1 (fr) Forme posologique a liberation continue pour administration orale
US8329215B2 (en) Shell and core dosage form approaching zero-order drug release
ZA912792B (en) Controlled release drug formulation
ATE477795T1 (de) Magenretentionssystem mit kontrollierter arzneimittelfreisetzung
AU1488295A (en) Pharmaceutical composition
HRP20161433T1 (hr) Doprema lijeka zadržavanjem u želucu za karbidopa/levodopa
CA2272586A1 (fr) Compositions medicinales a desintegration rapide
BG102438A (en) Medicamentous form
WO2003051304A3 (fr) Systeme d'administration de medicament bioadhesif a propriete de retention gastrique amelioree
EP2033648A3 (fr) Système d'administration de médicament à libération prolongée contenant des médicaments associés à un excipient
AU2002303897A1 (en) System for osmotic delivery of pharmaceutically active agents
ZA979937B (en) Delayed delivery system for acid-sensitive drugs
MY130332A (en) Pharmaceutical formulation comprising iota-carrageenan and at least one neutral gelling polymer
JPH0624959A (ja) 胃内浮遊型薬物徐放性固形製剤
CA2219777A1 (fr) Nanoparticules pour l'administration orale d'agents pharmaceutiques de faible solubilite
Park et al. Polymers in pharmaceutical products
Collette et al. Triblock Copolymers Self-Assembled in Vesicles: Applications to the Oral Delivery of Insulin
EP0375649A3 (fr) Système pour la délivrance orale des drogues à gonflement contrôlé
TH57760A3 (th) การลำเลียงแบบเอนเทอริกและโคโลนิก โดยใช้แคปซูลชนิด hpmc